Once CatL has been demonstrated to be important to the virus entry and possibly exit during late stages of infection, drugs exhibiting capacity of CatL inhibition could offer potential COVID-19 therapy, even considering they were not primarily developed for this purpose and their true role as COVID-19 treatment needs controlled clinical trials. This evidence concerns the gene CTSL and infection.